Rti surgical, inc (rti) and tutogen medical (b)(4) (tmi), a wholly owned subsidiary of rti, received a complaint as part of the fortiva appear trial.The reported complaint indicated that a patient underwent a right nipple conserving inframammary mastectomy with incision on underside of breast on (b)(6) 2019.Two drains were placed (1 in axilla was removed on (b)(6) 2019; second drain was placed in the chest wall over the matrix and removed on (b)(6) 2019).The patient was discharged on (b)(6) 2019 with no additional medications.On (b)(6) 2019, the patient was noticed to have skin redness and a major seroma.Several aspirations were performed (b)(6).The complications were resolved without residual effects.
|
The graft remains implanted.Therefore, a comprehensive records re-review was conducted.There were no departures noted, during records re-review that would negatively impact the manufacturing of xenografts from lot pd17210001.Manufacturing records indicated that serial id (b)(6) met all specifications and release criteria prior to distribution.There is one related complaints for the lot, also associated with the appear trial.Porcine dermis xenografts undergo a validated sterilization method: tutoplast®, which includes terminal sterilization by gamma irradiation after packaging.To date, our investigation indicates, that the reported complications are more likely associated with one or more extrinsic factors, rather than in intrinsic property of the fortiva porcine dermis xenograft.
|